Adefovir dipivoxil in (lamivudine-resistant) hepatitis B patients – Study 461 (continued)
After 16 weeks, patients in both the adefovir dipivoxil monotherapy and combination adefovir dipivoxil plus lamivudine groups achieved a similar reduction in serum HBV DNA levels from baseline (2.86 log10 and 2.87 log10 copies per ml, p < 0.0001), as compared to no change (0.00 log10 copies per ml) in patients treated with lamivudine 100 mg monotherapy.
At the end of the 32 weeks of treatment, 32 percent of patients who received adefovir dipivoxil monotherapy had lost the YMDD resistance mutation (as compared to none of the patients receiving lamivudine).